Skip to content

Preventive and therapeutic effect of Jinghua Weikang Capsule on antiplatelet drug-induced gastric and small intestinal mucosal injury: a multicenter, randomized, double-blind, controlled clinical trial

Preventive and therapeutic effect of Jinghua Weikang Capsule on antiplatelet drug-induced gastric and small intestinal mucosal injury: a multicenter, randomized, double-blind, controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029964
Enrollment
Unknown
Registered
2020-02-17
Start date
2016-01-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antiplatelet drug-induced gastric and small intestinal mucosal injury

Interventions

Treatment group A:Jinghua Weikang capsule
Control group:Placebo
Treatment group A:inghua Weikang capsule
Treatment group B:Teprenone

Sponsors

Department of Gastroenterology, China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 18 years of age or older, male or female; 2. those who plan to take antiplatelet drugs; 3. those who agree to undergo capsule endoscopy before and after treatment; 4. those who have negative 13C-Hp breath test; 5. Those who have not taken other drugs that can cause stomach upset; 6. Have the ability to give informed consent, can adhere to the visit plan of this study, and can complete all study evaluations.

Exclusion criteria

Exclusion criteria: 1. Contraindications for capsule endoscopy (patients with suspected digestive tract stenosis, patients with a history of abdominal surgery); 2. Patients who refuse to undergo Helicobacter pylori-related examination and treatment; 3. Peptic ulcer, digestion Patients with gastrointestinal bleeding and other digestive diseases; 4. Patients with acute cerebrovascular disease, acute myocardial infarction, trauma, infection, suspected or confirmed diseases such as malignant tumors and hematological disorders; 5. taken within 4 weeks PPI, H2RA, antibiotics or gastric mucosal protective agents; 6. those who are treated with drugs such as glucocorticoids, warfarin, heparin; 7. severe liver and kidney damage, blood, endocrine and other diseases; 8. pregnant women And pregnant or lactating women; 9. those with mental illness or severe neurosis, who cannot express subjective symptoms, who do not follow the doctor's advice during treatment, and who cannot guarantee that the medication is completed as required during the trial; 10. those who refuse or cannot accept.

Design outcomes

Primary

MeasureTime frame
Capsule endoscopy score;

Countries

China

Contacts

Public ContactJiangbn Wang

Department of Gastroenterology, China-Japan Union Hospital of Jilin University

zrlwangjb@medmail.com.cn+86 13578993125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026